371 results for "Neuroplasticity"
Ketamine and Esketamine Therapy in Affective Disorders: A Comprehensive Review of Mechanisms, Clinical Evidence, Safety, and Future Directions
Zenodo (CERN European Organization for Nuclear Research) – February 28, 2026
Summary
Ketamine and esketamine offer rapid relief for patients with Treatment-Resistant Depression (TRD), showing effects within hours. In clinical trials, intravenous ketamine demonstrated significant effectiveness, while intranasal esketamine received approval for acute suicidal ideation. Approximately one-third of patients typically fail standard antidepressant treatments. Though these glutamatergic modulators represent a promising shift from traditional monoaminergic therapies, they require careful monitoring due to potential adverse effects like dissociation and sedation. Continued investigation is essential to ensure long-term safety and effective maintenance strategies in psychiatric care.
Abstract
Major Depressive Disorder (MDD) and Bipolar Depression represent significant global health burdens because about one-third of patients who receive ...
Sex-dependent developmental changes in behavior, brain structure, functional connectivity, and sensory perception following exposure to psilocybin during adolescence
Neuropsychopharmacology – February 18, 2026
Summary
Exposure to psilocybin during adolescence leads to significant long-term developmental changes in brain structure and behavior. In a study with male and female mice, those given 3.0 mg/kg of psilocybin showed altered perception of rewarding and aversive stimuli, with males experiencing greater effects. MRI imaging revealed increased functional connectivity in the prefrontal cortex, hypothalamus, and thalamus. Notably, males exhibited reduced levels of neuroplasticity-related proteins and regional brain volume changes, highlighting the profound influence of psychedelics on adolescent brain development.
Abstract
Psilocybin is a hallucinogen with complex neurobiological and behavioral effects. Underlying these effects are changes in brain neuroplasticity. We...
Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience
OpenAlex – June 13, 2024
Summary
The profound psychological benefits of the serotonergic hallucinogen psilocybin may depend on remembering the experience. In a pharmacology experiment, 8 healthy participants received 25mg Psilocybin alongside Midazolam, a drug causing memory impairment. While consciously experiencing the psychedelic effects, participants showed reduced memory. Crucially, greater memory impairment tended to lessen positive psychological outcomes like insight and well-being. This neuroscience finding suggests neuroplasticity-related memory processes are integral to psilocybin's lasting effects in medicine, influencing behavior via neurotransmitter receptor influence.
Abstract
Abstract Aspects of the acute experience induced by the serotonergic psychedelic psilocybin predict symptomatic relief in multiple psychiatric diso...
Utilidades terapéuticas del ayahuasca
Libro Comunicaciones – January 01, 2020
Summary
Ayahuasca shows promising therapeutic benefits, particularly for conditions like addiction and depression. Clinical literature indicates significant reductions in alcohol and cocaine use among dependent patients, with 60% reporting decreased symptoms of depression after treatment. Neuroimaging studies reveal notable activation in brain areas linked to emotion and memory processing. Additionally, users often describe experiences akin to psychotherapy, enhancing introspection and personal reflection. The compound promotes neuroplasticity through its effects on serotonin receptors, potentially improving cognitive aspects such as attention and memory.
Abstract
Objetivo: Exponer los potenciales beneficios terapéuticos del uso de ayahuasca, desde la neurofarmacología y la evidencia clínica existente hasta e...
Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis
Molecular Psychiatry – November 29, 2024
Summary
A comprehensive meta-analysis of 29 studies reveals that psychedelics and related drugs, often explored in Drug Studies for conditions like Major Depression, do not elevate peripheral Brain-derived neurotrophic factor (BDNF) levels in humans. BDNF, a key neurotrophic factor, is a common biomarker for neuroplasticity in medicine and psychology. Despite its use, this analysis, spanning databases like PsycINFO, found a negligible effect size (0.024). This suggests peripheral BDNF may not reliably indicate rapid neuroplasticity changes, challenging assumptions in neuroscience and internal medicine about these compounds.
Abstract
Abstract Background Peripheral levels of brain-derived neurotrophic factor (BDNF) are often used as a biomarker for the rapid plasticity-promoting ...
Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms
Journal of Psychopharmacology – June 30, 2023
Summary
A single psilocybin dose doubled specific brain activity linked to neuroplasticity, measured via Electroencephalography (EEG), in 19 individuals with depression. This hallucinogen's antidepressant effect, unlike placebo, correlated with improved psychology. This Neuroscience finding, vital for Psychiatry and Medicine, suggests how this alkaloid influences neurotransmitter receptors. While distinct from anesthesia, these Psychedelics and Drug Studies highlight chemical synthesis's role in advancing our understanding of behavior.
Abstract
Background: Evidence suggests that serotonergic psychedelics (e.g. psilocybin), have rapid-acting and long-lasting antidepressant effects after a s...
Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial.
Clinical and translational science – May 01, 2025
Summary
A groundbreaking study reveals that extended exposure to DMT, a naturally-occurring psychedelic compound, is safe and well-tolerated in humans. Scientists administered controlled intravenous infusions of N,N-dimethyltryptamine to 29 healthy volunteers over 6 hours, monitoring its effects on brain function and safety. The treatment showed promise for promoting neuroplasticity, with potential applications in stroke recovery. Participants experienced only mild psychedelic effects, with no serious adverse reactions.
Abstract
The serotonergic psychedelic N,N-dimethyltryptamine (DMT) presumably stimulates neuroplasticity in vitro and in vivo, by which it may exert neuropr...
Developmental changes in brain structure and function following exposure to oral LSD during adolescence.
Scientific reports – August 11, 2024
Summary
Adolescent exposure to LSD leads to lasting changes in brain architecture without impacting cognitive or motor abilities. Advanced brain imaging revealed that multiple LSD doses altered gray matter structure, particularly affecting connections between sensorimotor cortex regions and memory centers. While brain volume remained unchanged, neuroplasticity shifts were observed through diffusion weighted imaging, especially in areas controlling sensation and movement. These findings reshape our understanding of how psychedelics influence developing brains.
Abstract
LSD is a hallucinogen with complex neurobiological and behavioral effects. Underlying these effects are changes in brain neuroplasticity. This is t...
Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, proof-of-principle, placebo-controlled and crossover, neuroimaging trial in depression
OpenAlex – December 28, 2023
Summary
Nearly one-third of individuals with Major Depressive Disorder don't respond to conventional antidepressant treatments, highlighting an urgent need in psychiatry. A clinical psychology crossover study involving 36 participants will use functional neuroimaging to investigate how psilocybin, a psychedelic alkaloid, acutely impacts mood and brain neuroplasticity. This medicine aims to reveal psilocybin's neurobiological mechanisms, comparing its effects on brain networks, like the default mode network, against a placebo. Understanding this influence on cognition and behavior is crucial for developing new neuroscience-informed approaches.
Abstract
Abstract Background: Major Depressive Disorder (MDD) is a leading cause of disability worldwide across domains of health and cognition, affecting o...
The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness
Psychoactives – February 26, 2024
Summary
Psychedelics like N,N-dimethyltryptamine (DMT) show remarkable promise in neuroscience, potentially transforming mental illness treatment. DMT promotes neuroplasticity by fostering new neural connections, crucial for healthy cognition and recovery from neurodegeneration. Its influence on serotonergic and other neurotransmitter receptors is being explored in drug studies. This chemical alkaloid holds therapeutic potential for conditions like depression, anxiety, and PTSD, enhancing brain function and well-being. The human brain, with its billions of neurons and trillions of synapses, may find new pathways to healing through such compounds.
Abstract
The human brain is an extraordinarily complex organ responsible for all aspects of cognition and control. Billions of neurons form connections with...
Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.
Trials – July 03, 2024
Summary
Psilocybin, the active compound in psychedelic mushrooms, shows promise in treating major depressive disorder. This groundbreaking trial examines how psilocybin affects brain networks in depression using advanced imaging. Fifty patients will receive either psilocybin or placebo, with researchers measuring cerebral blood flow and brain activity changes through functional magnetic resonance imaging.
Abstract
Major depressive disorder (MDD) is a leading cause of disability worldwide across domains of health and cognition, affecting overall quality of lif...
Participation of Ca2+-Calmodulin-Dependent Protein Kinase II in the Antidepressant-Like Effects of Melatonin.
Molecular pharmacology – August 16, 2024
Summary
The sleep hormone melatonin may be a powerful ally in fighting depression through its effects on brain chemistry. New findings show that melatonin activates important proteins in the brain that help regulate mood, memory, and neural connections. People with depression often have lower melatonin levels, but supplementation can boost brain plasticity and enhance the effects of other antidepressants, particularly when combined with ketamine.
Abstract
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine secreted by the pineal gland during the dark phase of the photoperiod. Its main function...
The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action
Frontiers in Pharmacology – December 03, 2020
Summary
Psilocybin, a psychedelic with antidepressant potential, significantly alters sleep architecture. In a study of 20 healthy volunteers (10 women), psilocybin prolonged rapid eye movement (REM) sleep latency and showed a trend towards decreased overall REM sleep duration. Electroencephalography revealed it suppressed slow-wave sleep activity in the initial sleep cycle, contrary to predictions. Non-rapid eye movement sleep remained unchanged. These findings, relevant to psychology and medicine, suggest psilocybin's unique influence on sleep stages, potentially via its neurotransmitter receptor influence, could underpin its antidepressant effects.
Abstract
Serotonergic agonist psilocybin is a psychedelic with antidepressant potential. Sleep may interact with psilocybin’s antidepressant properties like...
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury.
Progress in neuro-psychopharmacology & biological psychiatry – July 14, 2025
Summary
Remarkably, specific psychedelic compounds could offer a new path for healing traumatic brain injuries. Research suggests psilocybin and 5-MeO-DMT, known for promoting neuroplasticity and neuritogenesis, may alleviate damage from a concussion. These compounds appear to reduce harmful microglia inflammation and act as neurotrophic agents, enhancing synaptic plasticity. A review of existing data highlights their potential to restore brain function.
Abstract
Traumatic brain injury (TBI) is a significant global health challenge, with limited effective treatments for its acute and chronic consequences. TB...
Exploring DMT: Endogenous role and therapeutic potential.
Neuropharmacology – May 01, 2025
Summary
DMT, a natural compound found in humans and throughout nature, shows remarkable promise beyond its known psychedelic effects. Recent research reveals it plays key roles in brain protection and healing. The compound activates during stress and hypoxia, promoting neuroplasticity and offering anti-inflammatory benefits. DMT's ability to protect brain cells and enhance neural connections suggests potential therapeutic applications for various neurological conditions.
Abstract
N,N-Dimethyltryptamine (DMT) is a naturally occurring amine and psychedelic compound, found in plants, animals, and humans. While initial studies r...
Next generation antidepressants with novel mechanisms for treatment resistant depression.
Progress in brain research – January 01, 2023
Summary
Breakthrough treatments like ketamine and psilocybin are revolutionizing depression care by rapidly altering brain chemistry and consciousness. These psychedelics boost neuroplasticity - the brain's ability to form new connections - offering relief within hours instead of weeks. Recent clinical trials show promising results, with many treatment-resistant patients experiencing significant improvement after just a few sessions with these novel antidepressants.
Abstract
Evidence has suggested that the modulation of N-methyl-d-aspartate receptors (NMDARs) and 5-hydroxytryptamine receptors (5-HTRs) via the psychedeli...
Brain-epigenome wide association study (BEWAS) on the effects of two emerging psychedelics: ketamine & MDMA
bioRxiv Preprint Server – July 03, 2025
Summary
Psychedelics like ketamine and MDMA induce lasting changes in brain gene activity. These compounds alter how genes are turned on or off, impacting pathways crucial for neuroplasticity and immune function. Both show positive effects on mental processes, suggesting a shared molecular basis for their therapeutic potential in psychiatric health.
Abstract
Psychedelic compounds such as ketamine and MDMA have shown therapeutic promise for mood and trauma-related disorders, yet their molecular mechanism...
Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy
ACS Medicinal Chemistry Letters – October 10, 2025
Summary
A breakthrough in psychedelic therapy reveals a novel psilocin-psilocybin cocrystal that enhances neuroplasticity and functional activity. This innovative advance in Psychedelics and Drug Studies leverages sophisticated chemical synthesis and alkaloids to improve drug exposure. Crucially, adjunctive atypical antipsychotics modulate brain signaling, mitigating cardiac safety concerns linked to 5-HT2B receptors. This chemistry-enabled path promises durable neuroplastic responses, validated across organoid and animal models, offering a scalable and safer solution for therapeutic applications.
Abstract
A crystalline cocrystal of psilocin and psilocybin enhances exposure, neuroplasticity biomarkers, and functional activity, while adjunctive atypica...
Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review
Nutrients – November 20, 2021
Summary
Traditional antidepressants often fail to alleviate depression in Anorexia nervosa, a complex eating disorder where malnutrition impairs neuroplasticity and neurogenesis, affecting cognition. A compelling finding is that Ketamine, a rapid antidepressant, shows promise for Anorexia treatment. Neuroscience suggests Ketamine enhances neuroplasticity and neurogenesis, potentially addressing the underlying brain changes. This offers a new avenue in Medicine and Psychiatry for treating Anorexia and its comorbid Major depressive disorder, moving beyond current psychological approaches.
Abstract
Anorexia nervosa (AN) is a highly complex disorder to treat, especially in severe and enduring cases. Whilst the precise aetiology of the disorder ...
Repeated administration of the synthetic cannabinoid AKB48 induces serotonergic neuroadaptation in male and female mice: behavioural and immunohistochemical evidence.
Neuropharmacology – February 01, 2026
Summary
Repeated exposure to the Synthetic Cannabinoid AKB48 (PubChem CID: 57404063) significantly worsens responses to synthetic Hallucinogens like 2C-I (PubChem CID: 10267191) or 25I-NBOMe (PubChem CID: 10251906). This effect is more prolonged in male mice. Using a behavioral and immunohistochemical approach, these changes were linked to neuroplasticity in the serotoninergic system, specifically at 5-HT(2A) receptors and SERT in the cerebellum and cortex. Interestingly, this neuroplasticity occurred more rapidly and markedly in female mice, highlighting complex interactions between these substances.
Abstract
In the last years, Synthetic Cannabinoids (SCBs) have established themselves as one of the largest and most popular groups of Novel Psychoactive Su...
Separate or inseparable? Serotonin and dopamine system interactions may underlie the therapeutic potential of psilocybin for anorexia nervosa
Physiology & Behavior – May 20, 2025
Summary
Compelling neuroscience reveals psilocybin, a serotonergic psychedelic, offers significant hope for anorexia nervosa. This powerful alkaloid enhances cognitive flexibility and improves cognition by modifying reward processing. Neurochemical actions involve neuroplasticity, altering neural circuits within the prefrontal cortex and nucleus accumbens. Data from animal models and human imaging studies show its influence on both serotonin and dopaminergic pathways, impacting dopamine. This complex neurotransmitter receptor influence on behavior, a key area in psychology and psychedelics and drug studies, underpins its therapeutic potential.
Abstract
Psilocybin, a serotonergic psychedelic, has emerged as a promising treatment for a range of mental health conditions, including anorexia nervosa. R...
Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy
Biological Psychiatry Cognitive Neuroscience and Neuroimaging – February 09, 2024
Summary
Psychedelics and Drug Studies reveal that MDMA and serotonergic hallucinogens uniquely foster prosocial behavior, crucial for mental health. Both compounds alter self-perception and consistently dampen reactivity to negative social input, like social defeat, a key insight for Psychology. Neuroscience indicates both induce social neuroplasticity, promoting adaptive neural rewiring. While MDMA enhances social reward responses, its altered self-image effects differ from serotonergic compounds. Understanding these neurotransmitter receptor influences on behavior is vital for therapeutic strategies, informing fields like Forensic Toxicology and Drug Analysis about their distinct mechanisms.
Abstract
There has been renewed interest in the use of 3,4-methylenedioxy-methamphetamine (MDMA) and serotonergic psychedelics in the treatment of multiple ...
Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review
Frontiers in Psychiatry – March 31, 2020
Summary
For the 4.4% of the global population experiencing depression, a novel treatment strategy combining psilocybin, a potent hallucinogen, with mindfulness meditation shows promise. A review of 93 articles suggests both impact mood and neuroplasticity, vital for mental health. While psilocybin influences cognition via neural network changes, mindfulness meditation enhances prefrontal cortex regulation. This synergy could offer a powerful new psychotherapeutic treatment, potentially extending the benefits of psychedelics for anxiety and depression in clinical psychology.
Abstract
Depression is a major public health problem that affects approximately 4.4% of the global population. Since conventional pharmacotherapies and psyc...
Beyond the 5-HT2AReceptor: Classic and Nonclassic Targets in Psychedelic Drug Action
Journal of Neuroscience – November 08, 2023
Summary
Serotonergic psychedelics like psilocybin profoundly promote neuroplasticity, rewiring neural networks that may treat conditions like depression and anxiety. This complex drug action involves activating serotonin 5-HT 2A receptors, influencing perception and cognition. Pharmacology reveals these drugs also interact with other neurotransmitter receptors, impacting psychology and behavior. Future drug studies are exploring chemical synthesis to develop nonhallucinogenic derivatives. These aim to retain therapeutic benefits without the intense experience, offering safer options by modifying their molecular action.
Abstract
Serotonergic psychedelics, such as psilocybin and LSD, have garnered significant attention in recent years for their potential therapeutic effects ...
Cell-type specific transcriptional modulation by psilocybin induces sustained plasticity in mouse medial prefrontal cortex
OpenAlex – January 08, 2025
Summary
A single dose of psilocybin dramatically enhances communication within the prefrontal cortex, a key brain region for memory and neural mechanisms. This Neuroscience discovery reveals sustained neuroplasticity, with increased gene expression related to brain cell plasticity observed 24 hours later. Specifically, a deep layer neuron cell type, L5/6 NP, drives this biology. Drug studies show psilocybin's effects are mediated by 5-HT 2C receptors, not 5-HT 2A, highlighting a precise mechanism for psychedelics. This cell-type specific action offers new insights into neuroendocrine regulation and behavior.
Abstract
Abstract Despite enormous interest in psychedelics for psychiatric interventions, potential underlying biological mechanisms remain unclear. Here, ...
From fungi to pharmacy: Applied technologies in psilocybin production and its therapeutic applications
Creative Science – December 19, 2025
Summary
Psilocybin, a potent alkaloid, demonstrates rapid, sustained antidepressant efficacy in clinical trials, signaling a renaissance in Psychopharmacology. This naturally occurring compound, central to Psychedelics and Drug Studies, functions as a prodrug. Its active form modulates 5-HT2A receptors, enhancing neuroplasticity—a key mechanism explored in Neuroscience. Advances in chemical synthesis and microbial biosynthesis are revolutionizing its production, moving beyond traditional plant sources. This progress in Pharmacology and Drug discovery positions psilocybin as a transformative agent, bridging biological pathways from fungi to therapeutic applications.
Abstract
Psilocybin, a naturally occurring tryptamine alkaloid found in over 200 species of fungi, has emerged as a focal point in the modern revival of psy...
Psilocybin’s effect on human brain synaptic plasticity
OpenAlex – October 10, 2025
Summary
A single dose of psilocybin, a potent psychedelic compound, significantly boosts brain connectivity when administered in a therapeutic-like environment. Fifteen healthy participants experienced more intense mystical states and lasting psychological benefits, alongside greater synaptic density increases in the frontal cortex and hippocampus, compared to those dosed in an MRI scanner. This demonstrates how environmental context profoundly shapes the neuroplastic effects of such alkaloids, influencing neurotransmitter receptor activity and behavior. These findings have crucial implications for future drug studies.
Abstract
Abstract Psychedelics such as psilocybin have been linked to enhanced neuroplasticity and symptom relief in affective disorders, but the neurobiolo...
Therapeutic Effects of Psychedelics and their Non-Hallucinogenic Analogs on Depressive-Like Behaviour
Carleton undergraduate journal of science. – September 02, 2025
Summary
Major depressive disorder affects 280 million people globally, often resisting current treatments. While psilocybin, a hallucinogen, shows promise in Psychology and Psychedelics and Drug Studies by influencing neurotransmitter receptors, its properties limit accessibility. This research investigates whether non-hallucinogenic compounds, derived from chemical synthesis and alkaloid structures like 2-bromo-LSD, can offer similar antidepressant benefits. Using rodent models, it aims to determine if therapeutic neuroplasticity can occur without the hallucinatory experience, potentially providing more accessible options for treatment-resistant depression.
Abstract
Major depressive disorder (MDD) is a complex and debilitating condition affecting approximately 280 million people worldwide. Its heterogeneous nat...
The science of psychedelic medicine.
Nature medicine – February 06, 2026
Summary
Psychedelics profoundly alter brain function, creating a critical window for psychological and behavioral change. Understanding reveals two complementary processes: acute brain pattern destabilization and subacute neuroplasticity, enhancing the brain's capacity to adapt. These compounds demonstrate therapeutic potential across diverse neuropsychiatric conditions. Key challenges include reconciling subjective experience with therapeutic outcomes, managing risks of heightened brain plasticity, and streamlining regulatory approval. This evolving science could fundamentally reshape our understanding of how personal experience connects with biological brain changes in psychiatry.
Abstract
Classic psychedelics typically act at the serotonin 5-HT2A receptor to profoundly alter brain function and consciousness. Research on these compoun...
[Clinical application and mechanistic studies of psychedelics for treatment of depression: progress and future challenges].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University – January 20, 2026
Summary
A compelling new approach to depression treatment is emerging: **psychedelic**s. **Psilocybin**, for instance, demonstrates rapid, robust, and sustained **antidepressant** effects, even for treatment-resistant cases. These compounds remarkably enhance brain **neuroplasticity**, creating a critical therapeutic "window." While precise mechanisms are still being elucidated, the **5-hydroxytryptamine receptor 2A** pathway is a central focus. This offers a unique, fast-acting intervention for a prevalent global disorder, moving beyond the limitations of current medications.
Abstract
Depression is a complex and globally prevalent mental disorder, for which conventional antidepressant medications face limitations such as delayed ...
Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers
ACS Pharmacology & Translational Science – August 31, 2020
Summary
A compelling increase in brain-derived neurotrophic factor (BDNF) was observed following low doses of LSD. In a placebo-controlled study with 30 healthy volunteers, BDNF levels rose significantly at 4 hours after a 5 μg dose and at 6 hours for both 5 μg and 20 μg doses compared to placebo. This highlights psychedelic medicine's potential for enhancing neuroplasticity, crucial for therapeutic responses in internal medicine and psychology. The biochemical analysis suggests promising avenues for future studies in psychiatric populations.
Abstract
Despite preclinical evidence for psychedelic-induced neuroplasticity, confirmation in humans is grossly lacking. Given the increased interest in us...
Updated View on the Relation of the Pineal Gland to Autism Spectrum Disorders
Frontiers in Endocrinology – February 04, 2019
Summary
Low melatonin levels, linked to pineal gland dysfunction, may play a significant role in autism, affecting around 1 in 44 children. This hormone regulates sleep and circadian rhythms, with many autistic individuals experiencing sleep disorders. Abnormal neuroplasticity, such as cortical overgrowth, is also observed. The pineal gland could be a source of N,N-dimethyltryptamine (DMT), suggesting that both melatonin deficiency and DMT metabolism might contribute to autism's development. Exploring these connections could lead to innovative treatments involving melatonin and light exposure.
Abstract
Identification of the biological features of autism is essential for designing an efficient treatment and for prevention of the disorder. Though th...
Ayahuasca, DMT, and Mental Health: A Current Review of Scientific Studies
Current Addiction Reports – February 21, 2026
Summary
Ayahuasca, a traditional Amazonian brew, shows promise in treating various mental health disorders, including depression and PTSD. In human studies with 60 participants, neuroimaging revealed decreased default mode network activity and increased brain connectivity, suggesting enhanced neuroplasticity. Users often report emotional breakthroughs and heightened self-awareness. While findings are encouraging, especially for addressing core psychological processes, caution is advised for individuals with psychosis or bipolar disorder. Structured trials are essential to establish the safety and efficacy of ayahuasca as a therapeutic option in clinical psychology.
Abstract
Summarizes preclinical and clinical evidence on ayahuasca—a traditional Amazonian brew combining N, N-Dimethyltryptamine (DMT) and β-carbolines—in ...
Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential
Molecular Psychiatry – October 21, 2025
Summary
A novel compound, 5-Br-DMT, shows promise as a rapid-acting antidepressant without hallucinogenic effects. In a study with mice, a single dose of 10 mg/kg significantly reduced depressive-like behavior. This compound selectively activates serotonin receptors while promoting neuroplasticity through increased expression of genes associated with dendritic growth in the prefrontal cortex and hippocampus. The findings suggest that halogenated DMT derivatives could lead to new treatments for mood disorders, addressing limitations of traditional antidepressants like SSRIs, which often fail to benefit many patients.
Abstract
Current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRI), often present a delayed onset of action and fail to eff...
Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders.
Molecular psychiatry – January 01, 2024
Summary
Combining psychedelics with specific brain receptor modulators may enhance mental health treatment while reducing unwanted effects. New findings show that psilocybin and NMDA receptor compounds like D-serine work together to boost brain plasticity and mood improvement. This dual approach could offer more effective, safer treatment options for depression and other mental health conditions.
Abstract
Modern research data suggest a therapeutic role for serotonergic psychedelics in depression and other neuropsychiatric disorders, although psychoto...
Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.
The Journal of neuroscience : the official journal of the Society for Neuroscience – November 08, 2023
Summary
Psychedelic drugs like psilocybin and LSD work through multiple brain pathways, not just the well-known serotonin receptor system. These substances promote the formation of new neural connections and can rewire brain networks, explaining their potential benefits for mental health conditions. While their primary effects occur through serotonin receptors, they also interact with other key brain systems that influence mood and cognition. Scientists are now developing modified versions that could offer therapeutic benefits without hallucinogenic effects.
Abstract
Serotonergic psychedelics, such as psilocybin and LSD, have garnered significant attention in recent years for their potential therapeutic effects ...
Neuroimaging in psychedelic drug development: past, present, and future.
Molecular psychiatry – September 01, 2023
Summary
Brain scans reveal how psychedelic medicines like psilocybin and LSD work to treat mental health conditions. Modern imaging techniques show these drugs temporarily alter brain connectivity and receptor activity, particularly affecting serotonin systems. This helps explain their therapeutic effects on depression, PTSD, and addiction, while guiding the development of safer, more effective treatments.
Abstract
Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating psychiatric disorders, including depression, add...
Advances in the study of NMDA receptors in depression pathogenesis and the antidepressant efficacy of their antagonists.
Asian journal of psychiatry – June 01, 2025
Summary
Breakthrough brain research reveals why traditional antidepressants can take weeks to work, while newer treatments targeting NMDA receptors can lift severe depression within hours. These receptors, part of the brain's glutamatergic system, act like molecular switches affecting mood and memory. When blocked by specific NMDA receptor antagonists, they trigger rapid improvements in depressive symptoms, offering hope for patients who don't respond to conventional treatments.
Abstract
N-methyl-D-aspartate receptors (NMDA receptors) play a crucial role as ionotropic glutamate receptors in regulating neuroplasticity, learning, memo...
Breaking the cycle: a systematic review of neurobiological mechanisms and psychotherapeutic innovations in ketamine addiction.
Journal of addictive diseases – March 06, 2025
Summary
Recent findings reveal that ketamine addiction ("Special K") alters brain connectivity in ways similar to depression, but innovative treatment approaches show promise. By combining neurobiological markers with targeted psychotherapy, including CBT and EMDR, clinicians can now better triage and treat patients. This comprehensive treatment framework integrates neurobiology with personalized therapy timing, leading to significantly improved recovery rates compared to traditional approaches.
Abstract
This systematic review synthesizes current evidence on non-prescribed ketamine use, emphasizing its neurobiological impacts and psychotherapeutic i...
Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review.
International journal of molecular sciences – December 05, 2024
Summary
A protein called BDNF acts like brain fertilizer, helping neurons grow and connect. Recent findings show that ketamine and esketamine can rapidly boost BDNF levels in people with treatment-resistant depression, leading to significant mood improvements within hours. While traditional antidepressants take weeks to work, these newer treatments help restore brain connections quickly, offering hope for patients with major depressive disorder who haven't responded to other therapies.
Abstract
Brain-derived neurotrophic factor (BDNF) is critical for neuroplasticity, synaptic transmission, and neuronal survival. Studies have implicated it ...
Divergent Effects of Ketamine and the Serotoninergic Psychedelic 2,5-Dimethoxy-4-Iodoamphetamine on Hippocampal Plasticity and Metaplasticity.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2024
Summary
While ketamine and psychedelics both help treat mental health conditions, their effects on brain plasticity differ significantly. New research reveals that the psychedelic DOI enhances brain cell communication in the hippocampus 24 hours after treatment, while ketamine shows no such effect. DOI appears to work by boosting signal transmission between neurons, suggesting unique mechanisms for these promising therapeutic compounds.
Abstract
Serotonergic psychedelics and ketamine produce rapid and long-lasting symptomatic relief in multiple psychiatric disorders. Evidence suggests that ...
From antidepressants and psychotherapy to oxytocin, vagus nerve stimulation, ketamine and psychedelics: how established and novel treatments can improve social functioning in major depression.
Frontiers in psychiatry – January 01, 2024
Summary
Social impairments in major depressive disorder can be as debilitating as mood symptoms. While traditional antidepressants help some patients, breakthrough treatments like ketamine, psychedelics, and vagus nerve stimulation show promising results for restoring social connections. These novel approaches work differently than standard treatments - targeting brain plasticity and emotional processing to help people reconnect with others and rebuild relationships.
Abstract
Social cognitive deficits and social behavior impairments are common in major depressive disorder (MDD) and affect the quality of life and recovery...
ER stress in mouse serotonin neurons triggers a depressive phenotype alleviated by ketamine targeting eIF2α signaling.
iScience – May 17, 2024
Summary
Stress in brain cells that produce serotonin can trigger depression-like behavior in mice. This groundbreaking neuroscience finding shows how cellular stress disrupts serotonin production and brain plasticity. The antidepressant ketamine can rapidly reverse these effects by targeting specific molecular pathways, offering new insights into both depression's origins and treatment.
Abstract
Depression is a devastating mood disorder that causes significant disability worldwide. Current knowledge of its pathophysiology remains modest and...
Evidence of quantum-entangled higher states of consciousness.
Computational and structural biotechnology journal – January 01, 2025
Summary
No Summary
Abstract
What if quantum entanglement could accelerate learning by unlocking higher states of conscious experience? This study provides empirical and statis...
Lasting dynamic effects of the psychedelic 2,5-dimethoxy-4-iodoamphetamine ((±)-DOI) on cognitive flexibility
Molecular Psychiatry – February 06, 2024
Summary
A single dose of the psychedelic (±)-DOI dramatically enhances brain plasticity and cognitive flexibility in mice. One day after receiving 2 mgkg −1, mice exhibited increased volumes in several sensory and association areas, a form of structural flexibility. A week later, their cognition showed improved adaptation to new rules in a learning task, even adopting a unique strategy of learning from reward omissions. This lasting boost in behavioral flexibility, influenced by neurotransmitter receptor activity, offers insights for neuroscience, psychology, and medicine regarding neuropsychiatric disorders.
Abstract
Abstract Psychedelic drugs can aid fast and lasting remission from various neuropsychiatric disorders, though the underlying mechanisms remain uncl...
The potential of psychedelics for the treatment of Alzheimer's disease and related dementias.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – November 01, 2023
Summary
No Summary
Abstract
Alzheimer's Disease (AD) is a currently incurable but increasingly prevalent fatal and progressive neurodegenerative disease, demanding considerati...
Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?
Clinical Pharmacology & Therapeutics – October 05, 2023
Summary
The potential of psychedelics like psilocybin and mescaline for conditions such as anxiety is compelling, driving new clinical trials in psychiatry. These hallucinogens influence neurotransmitter receptors, but it's unclear if their benefits truly synergize with psychological support from a psychotherapist. Rigorous 2x2 factorial clinical trials are crucial. These drug studies, vital for clinical psychology, will precisely evaluate the individual and combined effects of psilocybin and psychotherapy, informing future chemical synthesis of alkaloids and ensuring cost-effective, safe treatments.
Abstract
Clinical trials of psychedelics have provided support for their potential efficacy and safety. Although most combined a psychedelic with psychologi...
694. INVESTIGATING THE POTENTIAL OF PSILOCYBIN FOR COMPULSIVE EATING IN A RAT MODEL OF BINGE EATING
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Psilocybin, a well-known hallucinogen, showed no effect on compulsive binge eating in a rat model, challenging some theories in Psychology and Psychiatry regarding its therapeutic potential for eating disorders. In a study involving 44 female rats, a 2 mg/kg dose of Psilocybin did not reduce the animals' compulsive behavior or food intake associated with binge-eating disorder. While Psilocybin influences Neurotransmitter Receptors and is explored in Clinical Psychology for various behaviors, these Psychedelics and Drug Studies suggest this particular application might require different approaches.
Abstract
Abstract Background Binge eating disorder (BED) is the most prevalent eating disorder, often associated with metabolic syndrome and other mental he...
BEHAVIORAL PHENOTYPING AND METABOLOMIC COMPARISON OF CHEMICALLY SYNTHESIZED PSILOCYBIN AND PSYCHEDELIC MUSHROOM EXTRACT IN A ZEBRAFISH DEPRESSION MODEL
The International Journal of Neuropsychopharmacology – February 01, 2025
Summary
Psychedelic mushroom extract may offer unique benefits beyond synthetic psilocybin for depression-like symptoms. In a pharmacology study, zebrafish experiencing induced depression-like states (n=8 per group) showed reversed behaviors after receiving psilocybin or a mushroom extract. While both treatments normalized swimming patterns, brain analysis revealed the mushroom extract yielded more neurotransmitter precursors. This suggests the complex chemical synthesis of mushroom compounds, beyond just psilocybin, could be crucial for clinical psychology and psychiatry, impacting neurotransmitter receptor influence on behavior within psychedelics and drug studies.
Abstract
Abstract Background Psilocybin research in depression has been generated using chemically synthesized psilocybin (PSI). Psychedelic mushrooms produ...
Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial.
BMC neuroscience – February 05, 2024
Summary
Tiny doses of lysergic acid diethylamide (LSD) may subtly rewire brain connections, revealed through advanced brain imaging. This groundbreaking research tracked neuroplasticity changes in 80 healthy men using dynamic causal modelling, showing how microdoses affect neural pathways and long-term potentiation in visual processing areas, particularly in specific brain layers.
Abstract
Microdosing psychedelics is a phenomenon with claimed cognitive benefits that are relatively untested clinically. Pre-clinically, psychedelics have...
[Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment].
Der Nervenarzt – March 01, 2025
Summary
Antidepressants work through complex interactions between brain chemistry and environmental factors. Recent findings reveal that both traditional and newer medications promote neuroplasticity while improving emotional processing. The therapeutic benefits emerge from a combination of drug effects and extrapharmacological factors, including social support and environmental context. This challenges the notion that these external elements are merely placebo effects.
Abstract
Novel antidepressive substances are challenging the explanations for the mechanisms of action of traditional psychopharmacology. What could be the ...
Should we skip the trip? Clinical implications of psychedelic-associated subjective effects and the potential role of non-hallucinogenic alternatives.
General hospital psychiatry – July 03, 2025
Summary
The unique subjective experiences linked to psychedelics might be central to their mental health benefits. This raises a key question: are these intense "trips" necessary for healing? Research explores if non-hallucinogenic compounds can offer similar brain benefits, like neuroplasticity, without the acute subjective effects. The positive results suggest both approaches have a vital role, broadening future psychiatric treatment options.
Abstract
The resurgence of interest in classical psychedelics brings both promise and challenges to psychiatric care. Increasing evidence supports the thera...
Ketamine-Assisted Psychotherapy for Generalized Anxiety Disorder: A Comprehensive Case Report with Integrated Neurophysiological Imaging Using Magnetoencephalography
medRxiv Preprint Server – February 25, 2025
Summary
Ketamine therapy's rapid impact on mood and anxiety is remarkable. A case explored how this therapy affects brain networks and activity in generalized anxiety. Treatment significantly reduced anxiety and depressive symptoms, improving cognitive attention. Brain imaging revealed increased functional connectivity across multiple brain networks and beneficial brain wave changes, suggesting enhanced neuroplasticity. This shows how ketamine therapy positively alters brain function for better mood and emotion regulation.
Abstract
This detailed case report explores the application of ketamine-assisted psychotherapy (KAP) in the treatment of a male patient in their late 30’s w...
Exploring the therapeutic convergence of meditation, psychedelics, and MDMA
Journal of Psychedelic Studies – April 17, 2025
Summary
Remarkably, meditation, psychedelics, and MDMA share common pathways for improving mental well-being. A comprehensive literature review indicates these modalities enhance emotional regulation, empathy, and neuroplasticity by influencing similar brain networks. Combining meditation with psychedelic or MDMA-assisted therapy shows promise for stabilizing therapeutic insights, leading to sustained positive results and reduced distress. This convergence offers a powerful new approach for mental health.
Abstract
AbstractBackground and aimsPsychedelic and MDMA-assisted psychotherapy are at the forefront of new treatment models for mental illnesses such as PT...
Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.
International journal of molecular sciences – September 14, 2025
Summary
A key insight into schizophrenia reveals an excessive loss of brain connections, driven by overactive microglia and a gene called complement 4. This leads to reduced synaptic density, measurable by SV2A levels, profoundly affecting cognition, negative symptoms, and psychosis. Intriguingly, preclinical research shows psychedelics like LSD and psilocybin can promote neuroplasticity and synaptogenesis. Microdosing these compounds could restore crucial brain circuits, offering a promising path to rebuild connections and improve patient outcomes.
Abstract
Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In ...
Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives
ACS Chemical Neuroscience – June 06, 2025
Summary
Millions worldwide suffer chronic pain, often with depression. Neuroscience and Drug Studies reveal classic psychedelics, like psilocybin and LSD, which are alkaloids, offer a compelling new frontier in Medicine. These substances, influencing neuroplasticity and primarily acting on serotonin 5-HT2A receptors, appear to modulate pain perception and mood. Early evidence from case studies and preclinical research suggests they may alleviate conditions such as migraines and fibromyalgia. While exact mechanisms require further study, rigorous trials are vital to establish their therapeutic role in Psychology and Medicine, potentially guided by psychotherapists for mood aspects.
Abstract
Millions worldwide suffer from chronic pain, a complex condition often accompanied by depression and anxiety, highlighting the urgent need for inno...
Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium.
Journal of psychopharmacology (Oxford, England) – May 28, 2025
Summary
Psychedelics like psilocin can rewire brain connections similarly to established psychiatric medications. New research shows psilocin promotes neuroplasticity and new neural connections as effectively as ketamine and lithium - outperforming traditional antidepressants. While DMT and LSD showed minimal effects, psilocin triggered specific brain proteins linked to learning and memory formation.
Abstract
Recent evidence suggests that psychedelics can induce rapid and long-lasting antidepressant effects. The generally acknowledged explanation for the...
Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome.
Journal of clinical gastroenterology
Summary
Groundbreaking research reveals that psychedelics, combined with therapy, may offer relief for millions suffering from IBS and related disorders of gut-brain interaction. The treatment shows promise in addressing both physical pain and psychological distress by targeting shared neural pathways. Studies indicate psychedelic therapy could help rewire brain-gut connections and reduce symptoms through its unique ability to promote neuroplasticity.
Abstract
Irritable bowel syndrome (IBS) is prevalent and can be disabling. Many patients remain symptomatic despite behavioral and medical therapies. Psyche...
Psilocybin as a novel treatment for chronic pain
British Journal of Pharmacology – November 29, 2024
Summary
Psilocybin, a potent hallucinogen, holds significant promise in medicine for chronic pain relief. Neuroscience investigations reveal its anti-nociceptive potential, particularly for neuropathic and inflammatory pain. This psychedelic drug influences serotonergic pathways, demonstrating neuroplasticity by improving brain connectivity relevant to pain. Its chemical synthesis and alkaloid nature allow it to modulate specific neurotransmitter receptors, profoundly influencing behavior. Such insights from Psychology and Drug Studies indicate a new frontier for managing severe chronic pain, addressing both its physical and emotional components.
Abstract
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐noci...
Psychedelics for the Treatment of Obsessive–Compulsive Disorder: Efficacy and Proposed Mechanisms
The International Journal of Neuropsychopharmacology – November 29, 2024
Summary
Psilocybin, a potent hallucinogen, shows promise for treating obsessive-compulsive disorder (OCD). A small 2006 clinical trial demonstrated it significantly reduced OCD symptoms, aligning with historical accounts and rodent studies. While psychedelics are emerging in psychology for anxiety and depression, the exact mechanisms for OCD relief remain unclear. Hypotheses in psychiatry involve acute pharmacological effects, neuroplasticity, and psychological shifts. Current drug studies are evaluating this neurotransmitter receptor influence on behavior to inform future psychotherapist approaches, potentially transforming clinical mental health care.
Abstract
Abstract Psychedelics are emerging as potential treatments for a range of mental health conditions, including anxiety and depression, treatment-res...